Figure 1.

Anti-amyloid immunotherapy with 6G1 and A-887755 antibodies has no effect on fibrillar plaque growth and density. 6G1 recognize monomeric, oligomeric and fibrillar amyloid-β (Aβ), A-887755 recognizes only oligomeric amyloid-β. (A) Timeline of experimental procedures. Methoxy-X04 was applied 24 h before in vivo imaging, immunotherapy was administered immediately afterwards. (B) Chronic in vivo imaging of fibrillar plaques. Maximum intensity projections of volumes are shown, while analyses were performed in 3D. Changes from the previous time points are colour-coded. Scale bars = 10 µm. (C) Overall plaque densities at the last imaging session (8 weeks). (D) Volumes of pre-existing plaques, i.e. plaques that were present at the first imaging session, and (E) volumes of newborn plaques, i.e. plaques that appeared during the treatment period. (F) Linear growth rates of pre-existing plaques. Linear growth is proportional to the cube root of the differences of plaque volumes. (G) Linear growth rates of newborn plaques. (C–G) Box-and-whiskers plots show median, 25th and 75th percentiles (box) as well as minimum and maximum values (whiskers). Groups were compared using Kruskal-Wallis tests. No significant differences were found between groups (P > 0.05).